AFFLUENT MEDICAL SAS EO 1

Research AFFLUENT MEDICAL SAS EO 1 (0JZ) on Bullrun: market cap EUR 404.53M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is EUR 404.53M.

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025EUR 0-EUR 24.97M-EUR 11.67Mn/a-0.63EUR 1.75MEUR 22.94MEUR 5.76M
FY2024EUR 4.12M-EUR 14.74M-EUR 11.47M20.8%-0.38EUR 1.23MEUR 16.33MEUR 30.27M
FY2023EUR 0-EUR 15.65M-EUR 12.24Mn/a-0.51EUR 1.66MEUR 16.84MEUR 31.53M
FY2022EUR 0-EUR 15.23M-EUR 11.23Mn/a-0.81EUR 2.58MEUR 17.74MEUR 33.83M
FY2021EUR 0-EUR 14.82M-EUR 12.70Mn/a-0.88EUR 11.41MEUR 19.75MEUR 43.54M

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-27EUR 404.53Mn/an/a0

Dividend history

Latest trailing dividend snapshot: annual dividend/share 0 EUR.

About AFFLUENT MEDICAL SAS EO 1

Carvolix SA, a medical technology company, develops and markets minimally invasive minimally invasive medical devices in the field of urology and structural heart in France. It offers Artus, an implantable electro-mechanical artificial sphincter that targets moderate to severe urinary incontinence; and Kalios and Epygon implants for the treatment of mitral insufficiency, as well as Kardiozis technology for treating abdominal aortic aneurysm.

Related stock research

Other Healthcare stocks

Frequently asked questions

What is AFFLUENT MEDICAL SAS EO 1's market cap?

AFFLUENT MEDICAL SAS EO 1's market capitalization is EUR 404.53M.

What does AFFLUENT MEDICAL SAS EO 1 do?

Carvolix SA, a medical technology company, develops and markets minimally invasive minimally invasive medical devices in the field of urology and structural heart in France. It offers Artus, an implantable electro-mechanical artificial sphincter that targets moderate to severe urinary incontinence; and Kalios and Epygon implants for the treatment of mitral insufficiency, as well as Kardiozis technology for treating abdominal aortic aneurysm. The company was formerly known as Affluent Medical SA and changed its name to Carvolix SA in February 2026.